S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
S&P 500   4,551.68
DOW   35,490.69
QQQ   380.00
NASDAQ:REGN

Regeneron Pharmaceuticals Earnings Date, Estimates, & History

$589.60
-2.55 (-0.43 %)
(As of 10/27/2021 04:00 PM ET)
Add
Compare
Today's Range
$587.70
$594.09
50-Day Range
$543.48
$680.96
52-Week Range
$441.00
$686.62
Volume
658,057 shs
Average Volume
857,344 shs
Market Capitalization
$63.06 billion
P/E Ratio
10.59
Dividend Yield
N/A
Beta
0.16

Earnings Summary

Upcoming
Earnings Date
Nov. 4
Confirmed

Actual EPS
(Aug. 5)
$25.80
Beat By $16.99

Consensus EPS
(Aug. 5)
$8.81

Last Year's Q3 EPS
(8/5/2020)
$7.16

Skip Charts & View Estimated and Actual Earnings Data

Regeneron Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Regeneron Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20211$1.99$1.99$1.99
Q3 20212$10.76$11.01$10.89
Q4 20212$21.29$26.39$23.84
20215$34.04$39.39$36.72
Q1 20221$13.22$13.22$13.22
Q2 20222$9.94$14.30$12.12
Q3 20221$15.55$15.55$15.55
Q4 20221$16.15$16.15$16.15
FY 20225$54.86$59.22$57.04

REGN Earnings Information

Regeneron Pharmaceuticals last announced its quarterly earnings data on August 5th, 2021. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.81 by $16.99. The business had revenue of $5.14 billion for the quarter, compared to analyst estimates of $3.90 billion. Regeneron Pharmaceuticals has generated $28.66 earnings per share over the last year ($55.69 diluted earnings per share) and currently has a price-to-earnings ratio of 10.6. Earnings for Regeneron Pharmaceuticals are expected to decrease by -15.03% in the coming year, from $51.91 to $44.11 per share. Regeneron Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, November 4th, 2021. Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
11/4/2021
(Confirmed)
 $9.54       
8/5/20216/30/2021$8.81$25.80+$16.99$27.97$3.90 billion$5.14 billion    
5/6/20213/31/2021$7.78$9.89+$2.11$10.09$2.69 billion$2.53 billion  
2/4/202112/31/2020$7.11$9.53+$2.42$7.20$2.40 billion$2.42 billion  
11/5/20209/30/2020$9.52$8.36($1.16)$7.97$2.09 billion$2.29 billion  
8/5/20206/30/2020$5.59$7.16+$1.57$4.97$1.74 billion$1.95 billion  
5/5/20203/31/2020$6.13$6.60+$0.47$6.31$1.81 billion$1.83 billion  
2/6/2020Q4 2019$6.03$7.50+$1.47$6.23$2.10 billion$2.17 billion  
11/5/2019Q3 2019$5.13$6.67+$1.54$5.82$1.98 billion$2.05 billion  
8/6/2019Q2 2019$4.60$5.29+$0.69$8.90$1.80 billion$1.93 billion  
5/7/20193/31/2019$5.24$4.45($0.79)$3.51$1.76 billion$1.71 billion  
2/6/201912/31/2018$5.10$6.84+$1.74$4.69$1.73 billion$1.93 billion
11/6/20189/30/2018$4.94$5.87+$0.93$5.03$1.64 billion$1.66 billion
8/2/2018Q2 2018$4.60$5.45+$0.85$4.58$1.56 billion$1.61 billion
5/3/2018Q1 2018$5.08$4.67($0.41)$3.80$1.50 billion$1.51 billion
2/8/2018Q4 2017$4.18$5.23+$1.05$7.42$1.50 billion$1.58 billion
11/8/2017Q3 2017$3.83$3.99+$0.16$3.32$1.45 billion$1.50 billion
8/3/2017Q2 2017$2.67$4.17+$1.50$4.42$1.36 billion$1.47 billion  
5/4/2017Q1 2017$2.50$2.92+$0.42$2.16$1.30 billion$1.32 billion  
2/9/2017Q4 2016$2.51$2.19($0.32)$2.19$1.30 billion$1.23 billion  
11/4/2016Q3 2016$2.27$2.41+$0.14$2.55$1.29 billion$1.22 billion
8/4/2016Q2 2016$1.73$2.11+$0.38$2.53$1.24 billion$1.21 billion
5/5/2016Q1 2016$1.24$1.45+$0.21$1.45$1.18 billion$1.20 billion
2/9/2016Q4 2015$2.70$1.46($1.24)$1.58$1.17 billion$1.10 billion  
11/4/2015Q3 2015$2.62$2.59($0.03)$3.36$1.05 billion$1.14 billion  
8/4/2015Q2 2015$1.81$2.36+$0.55$3.03$887.03 million$999.00 million  
5/7/2015Q1 2015$2.50$1.99($0.51)$3.32$820.30 million$870.00 million
2/10/2015Q4 2014$2.08$2.11+$0.03$3.26$775.42 million$802.00 million
11/4/2014Q3 2014$2.10$1.90($0.20)$3.10$733.04 million$726.00 million
8/5/2014Q2 2014$2.33$1.89($0.44)$2.96$647.99 million$666.00 million  
5/8/2014Q1 2014$0.98$1.57+$0.59$2.56$609.04 million$626.00 million
2/11/2014Q4 2013$1.01$2.06+$1.05$3.26$579.17 million$610.00 million
11/5/2013Q3 2013$0.99$2.02+$1.03$2.79$501.93 million$597.00 million
8/6/2013Q2 2013$0.86$1.36+$0.50$1.93$470.63 million$458.00 million
5/3/2013Q1 2013$1.06$1.32+$0.26$1.74$424.26 million$440.00 million  
2/14/2013Q4 2012$1.11$1.47+$0.36$392.64 million$415.00 million  
10/24/2012$1.14$1.89+$0.75  
7/25/2012$0.45$0.90+$0.45
4/26/2012($0.33)$0.37+$0.70
2/13/2012($0.60)($0.37)+$0.23  
10/27/2011Q3 2011($0.75)($0.68)+$0.07($0.68)
7/28/2011($0.40)($0.69)($0.29)
5/3/2011Q1 2011($0.38)($0.49)($0.11)($0.49)
2/17/2011Q4 2010($0.32)($0.17)+$0.15($0.17)
10/28/2010Q3 2010($0.34)($0.41)($0.07)($0.41)
7/28/2010Q2 2010($0.38)($0.31)+$0.07($0.31)
4/29/2010Q1 2010($0.49)($0.38)+$0.11($0.38)
2/18/2010Q4 2009($0.34)($0.46)($0.12)($0.46)
11/3/2009Q3 2009($0.23)($0.01)+$0.22($0.01)
8/4/2009Q2 2009($0.28)($0.19)+$0.09($0.19)
4/30/2009Q1 2009($0.29)($0.22)+$0.07($0.22)
2/26/2009Q4 2008($0.30)($0.40)($0.10)($0.40)
11/4/2008Q3 2008($0.32)($0.27)+$0.05($0.27)
7/31/2008Q2 2008($0.35)($0.22)+$0.13($0.20)
5/1/2008Q1 2008($0.34)($0.15)+$0.19($0.15)
2/27/2008Q4 2007($0.46)($0.19)+$0.27($0.19)
(Earnings results data provided by Zacks Investment Research)












Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings Frequently Asked Questions

When is Regeneron Pharmaceuticals's earnings date?

Regeneron Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, November 4th, 2021. Learn more on REGN's earnings history

Did Regeneron Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $25.80 earnings per share (EPS) to beat the analysts' consensus estimate of $8.81 by $16.99. Learn more on REGN's earnings details

How can I listen to Regeneron Pharmaceuticals's earnings conference call?

The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Regeneron Pharmaceuticals's conference call transcript?

The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $8.50 billion.

How much profit does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.51 billion. REGN has generated $28.66 earnings per share over the last four quarters.

What is Regeneron Pharmaceuticals's price-to-earnings ratio?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 10.59 and a forward price-to-earnings ratio of 11.36. The price/earnings-to-growth ratio is 0.77.

What is Regeneron Pharmaceuticals's EPS forecast for next year?

Regeneron Pharmaceuticals's earnings are expected to decrease from $51.91 per share to $44.11 per share in the next year, which is a -15.03% change.

This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.